TITLE

Treatment of Cystinuria

AUTHOR(S)
Lotz, Myron; Bartter, Frederic C.
PUB. DATE
March 1965
SOURCE
British Medical Journal;3/27/1965, Vol. 1 Issue 5438, p855
SOURCE TYPE
Academic Journal
DOC. TYPE
Letter
ABSTRACT
No abstract available.
ACCESSION #
64058193

 

Related Articles

  • Tiopronin.  // Reactions Weekly;3/12/2011, Issue 1342, p30 

    The article describes the case of a boy with cystinuria who developed nephrotic syndrome while undergoing tiopronin treatment.

  • Penicillamine: Twenty-Five Years Later. Crawhall, John C. // Annals of Internal Medicine;Aug80, Vol. 93 Issue 2, p367 

    Comments on the efficacy of penicillamine for the treatment of Wilson's disease. Rationale for the use of penicillamine in cystinuria; Effect of penicillamine therapy in rheumatoid arthritis; Dosage considerations for the drug.

  • Tiopronin: Minimal change disease and acute kidney injury: case report.  // Reactions Weekly;Jun2019, Vol. 1756 Issue 1, p325 

    A case study of a 48-year-old man is presented, who developed minimal change disease and acute kidney injury during treatment with tiopronin for cystinuria.

  • Pseudoxanthoma elasticum-like skin changes induced by pecnicillamine. Thomas, R. H. Meyrick; Light, N.; Avery, N. C.; Stephens, A. D.; Kirby, J. D. T. // Journal of the Royal Society of Medicine;Sep1984, Vol. 77 Issue 9, p794 

    The article presents the case of a patient who developed penicillamine dermopathy following high-dose D-penicillamine therapy for cystinuria. The patient who is a 59-year-old man was diagnosed as having cystinuria at the age of 37 years. D-penicillamine is used for the treatment of rheumatoid...

  • Canine cystinuria: polymorphism in the canine SLC3A1 gene and identification of a nonsense mutation in cystinuric Newfoundland dogs. Henthorn, Paula S.; Junlong Liu; Gidalevich, Tanya; Jikang Fang; Casal, Margret L.; Patterson, Donald F.; Giger, Urs // Human Genetics;Oct2000, Vol. 107 Issue 4, p295 

    Cystinuria is an inherited renal and intestinal disease characterized by defective amino acid reabsorption and cystine urolithiasis. Different forms of the disease, designated type I and non-type I in cystinuric humans, can be distinguished clinically and biochemically, and have been associated...

  • Cystine calculi: challenging group of stones. Ahmed, Kamran; Dasgupta, Prokar; Khan, Mohammad Shamim // Postgraduate Medical Journal;Dec2006, Vol. 82 Issue 974, p799 

    Cystinuria is an autosomal recessive disorder in renal tubular and intestinal transport of dibasic amino acids, which results in increased urinary excretion of cystine, ornithine, lysine and arginine. It affects 1 in 20 000 people and is caused by a defect in the rBAT gene on chromosome 2....

  • Cystinuria subtype and nephrolithiasis. Guillen, Marisa; Corella, Dolores // Kidney International;Jul1999, Vol. 56 Issue 1, p353 

    Presents a letter to the editor of 'Kidney International' periodical concerning cystinuria subtype and risk of nephrolithiasis. Genetic epidemiology of cystinuria; Biochemical classification of cystinuria.

  • Cystinuria: mechanisms and management. Claes, Donna; Jackson, Elizabeth // Pediatric Nephrology;Nov2012, Vol. 27 Issue 11, p2031 

    Cystinuria is a relatively uncommon cause of pediatric stone disease, but has significant morbidity if not properly controlled because of its significant stone recurrence rate. Cystinuria is caused by the inability of the renal tubules to reabsorb filtered cystine, which is poorly soluble at a...

  • Evaluation of Medical Cystine Stone Prevention in an Animal Model. Sagi, Sreedhar; Wendt-Nordahl, Gunnar; Alken, Peter; Knoll, Thomas // AIP Conference Proceedings;2007, Vol. 900 Issue 1, p417 

    Medical treatment for cystinuria aims to decrease the concentration of cystine in the urine, increase its solubility and therefore prevent stone formation. Ascorbic acid and captopril have been recommended as alternatives to thiol drugs, though conflicting data undermining their efficacy has...

  • Myopathy due to mercaptopropionyl glycine. Hales, D.S.M.; Scott, R.; Lewi, H.J.E. // British Medical Journal (Clinical Research Edition);10/2/1982, Vol. 285 Issue 6346, p939 

    Examines the reduction of urinary cystine concentration to manage the cystinuria. Prevention of cystine precipitation and stone formation; Development of myopathy after the use of mercaptopropionyl glycine used to treat cystinuria; Characteristics of the cystinuria.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics